Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety and immunogenicity trial of IXCHIQ in pregnant women in Brazil

Trial Profile

A Safety and immunogenicity trial of IXCHIQ in pregnant women in Brazil

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 1553 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions

Most Recent Events

  • 04 Aug 2024 New trial record
  • 22 Jul 2024 According to a Valneva media release, this trial will be- Part- funded by CEPI and the EU's Horizon Europe program. The trial is expected to start in 2025. Trial partners, including clinical research organisations and trial sponsors, are expected to be selected over the coming months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top